Latest news with #biopharmaceutical
Yahoo
7 minutes ago
- Business
- Yahoo
Jim Cramer on Bristol-Myers: 'Never Seen it This Cheap'
Bristol-Myers Squibb Company (NYSE:BMY) is one of the stocks Jim Cramer reflected on. When asked about the stock during the lightning round, Cramer replied that he is holding out hope for the company's 'central nervous system drug.' 'Bristol Myers, never seen it this cheap. We're holding it. I did have high hopes for their, what, what I would say is their central nervous system drug. It better work. If it doesn't work, we're going to get rid of it, and it will be a disappointment, and it will be a shame.' Bristol-Myers (NYSE:BMY) develops and markets biopharmaceutical products targeting cancer, cardiovascular conditions, immune disorders, and neurological diseases. The company's portfolio includes Eliquis, Opdivo, Revlimid, and other treatments for serious and chronic illnesses. During a June episode, Cramer showed disappointment in the stock, as he commented: 'Bristol Myers, Charitable Trust owns it. So far, we're not happy with COBENFY. It's a little disappointing. We need to see that stock back up at 60.' While we acknowledge the potential of BMY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
7 minutes ago
- Business
- Yahoo
Heavy Insider Selling at ADMA Biologics Despite Earnings Strength
ADMA Biologics, Inc. (NASDAQ:ADMA) is one of the . The company witnesses significant insider sales amid strong growth and strategic advances reported in the Q1 earnings report. An independent distributor in their pharmacy with a range of biopharmaceutical products on display. Headquartered in New Jersey, ADMA Biologics, Inc. (NASDAQ:ADMA) is the only U.S.-based producer of plasma-derived immunoglobulin therapies. The company is engaged in the process of developing, manufacturing, and commercializing FDA-approved products, including ASCENIV, BIVIGAM, and Nabi-HB, to prevent and treat infectious diseases in immunodeficient and at-risk patients. On May 7, 2025, the company reported its first quarter earnings report for 2025. With a solid 40% year-over-year increase in total revenues, reaching $114.8 million, the company raised its 2025 revenue guidance to more than $500 million. Additionally, the company has also announced a $500 million stock repurchase program, which reflects its confidence in its financial stability. Later, on June 4, 2025, the company's top executives started selling the company's shares. Significant among them was the sales made by Director Steve Elms, who sold 425,621 shares, worth the value of $8,829,333. Despite the potential hit these transactions could have had on the investor's confidence, ADMA Biologics, Inc. (NASDAQ:ADMA)'s anticipated 5-year EPS growth continues to stand high at 39.37% while volatility remains low with a beta of 0.38. While we acknowledge the potential of ADMA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Metal Stocks with Insider Buying in 2025 and 10 Energy Stocks with Insider Buying in 2025 Disclosure. None. Sign in to access your portfolio
Zawya
3 hours ago
- Business
- Zawya
Takeda appoints Hernán Porcile as Head of the EAMEA region, continuing its legacy of visionary leadership
From his new base in Dubai, a key international gateway, Hernán will steer Takeda's strategic priorities across diverse, fast-growing EAMEA (Eurasia, the Middle East, and Africa) markets Dubai, United Arab Emirates - Takeda, a global, research and development-driven biopharmaceutical leader, has appointed Hernán Porcile as the new Area Head for its Eurasia, Middle East and Africa (EAMEA) region. Formerly General Manager of Takeda Mexico, Hernán Porcile assumed his new role on July 1, 2025, and is now based in Dubai, United Arab Emirates, from where he will lead the company's strategic developments and accelerate growth across the diverse region. Hernán's appointment comes at a pivotal moment as Takeda intensifies its focus on advancing sustainable, value-based healthcare across the region. Building on the company's strong foundation, Hernán will deepen collaboration with key stakeholders, strengthen local systems, and drive innovation through scientific exchange and partnerships, further reinforcing Takeda's long-term commitment to resilient healthcare infrastructure and fostering a lasting impact. ' The EAMEA region's rapidly evolving healthcare landscape presents tremendous opportunities for Takeda, particularly as key markets in the region pursue bold national visions. As a purpose-driven, patient-centric company, we are proud to contribute to these transformative efforts by advancing access to innovative and high-quality healthcare solutions. The region remains a strategic growth priority for Takeda, as we continue to invest in sustainable healthcare solutions and deepen our presence across key markets, ' said Hernán Porcile, Takeda's newly appointed EAMEA Area Head. Hernán joined Takeda in 2009 as Administration and Finance Director in Argentina and has since held several leadership roles, including serving as Head of Takeda Mexico and Colombia. He has also overseen operations across Latin America, covering the Southern Cone, Andean Region, Mexico, and Central America. Throughout his career, he has led key transformation initiatives and strategic projects, with expertise spanning finance, commercial development, and gastroenterology. Notably, he oversaw the successful launch of three critical therapies aimed at improving outcomes for patients with multiple myeloma, hereditary angioedema, and inflammatory bowel disease. Prior to joining Takeda, he spent over 12 years at Schering-Plough. Hernán also serves as Secretary of the Mexican Association of Pharmaceutical Research Industries (AMIIF), where he leads the Clinical Research Commission. He holds a degree in Public Accounting from the University of Morón in Argentina and an MBA in Strategy from the University of Belgrano. With deep expertise in emerging markets and a strong track record of transformational leadership, Hernán is poised to play a pivotal role in advancing Takeda's mission to deliver better health and a brighter future to patients across the Eurasia, Middle East and Africa area. About Takeda Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries.
Yahoo
4 hours ago
- Business
- Yahoo
AstraZeneca Plans to Invest $50 Billion in U.S. by 2030
The biopharmaceutical company said the investment includes plans for a new manufacturing center focused on chronic diseases. Sign in to access your portfolio
Yahoo
10 hours ago
- Business
- Yahoo
Ipsen announces changes to its Executive Committee
PARIS, FRANCE, 23 July 2025 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty care biopharmaceutical company, today announced the following changes to its Executive Committee: Mari Scheiffele is appointed to EVP, Chief Product Officer Andreas Gerber is appointed to EVP, Head of International Caroline Sitbon is appointed to EVP, General Counsel Mari, Andreas and Caroline will report to Ipsen's Chief Executive Officer, David Loew, beginning September 1, 2025. After 4 years successfully leading the commercial operations for the International Region at Ipsen, Mari Scheiffele will now lead all medicines in Oncology and Rare Disease at Ipsen. In the new role, Mari will focus on driving product development and pipeline innovation for new medicines and lead globally, brands and life cycle management. Mari succeeds Bartek Bednarz who will now lead the newly created Asia, Pacific & China region at Ipsen. Andreas Gerber joins Ipsen from Johnson & Johnson where he most recently served as Worldwide Vice-president and Head of the Oncology Franchise. In his new role as Head of International, Andreas will lead Ipsen's operations in all geographies excluding North America. Andreas's extensive business acumen and commercial operations experience will support driving growth in Ipsen's three therapeutic areas: Oncology, Rare Disease and Neuroscience across the International region. Andreas succeeds Mari Scheiffele. Finally, Caroline Sitbon has been promoted to the role of Ipsen's General Counsel. Caroline joined the company from GSK in 2024 as Senior Vice President, Legal Affairs. In her new role, Caroline will lead legal and business ethics and will also serve as the Board of Directors' General Secretary. Caroline succeeds François Garnier who will be retiring after a very successful career, including his tenure as Ipsen's General Counsel and General Secretary to the Board of Directors. 'These three appointments bring additional highly qualified global leaders to our executive leadership team and I'm delighted that they represent a combination of internal promotions and new leaders that have joined Ipsen,' said David Loew, Chief Executive Officer. 'After personally working with both Mari and Caroline throughout their tenure at Ipsen, I have been impressed by their leadership, business insights and innovative mindsets. Each of these leaders, in their respective fields, have strongly contributed and partnered with Executive Leadership Team members to the ongoing transformation that we have been successfully driving at Ipsen. I am also very pleased to welcome Andreas to Ipsen. Over the last few years, I have observed his accomplishments and am convinced that his leadership and capacity to inspire our teams to execute and deliver on our strategy will be instrumental in our continuous growth trajectory in those respective markets. These additions also now represent a gender-balanced Executive Committee at Ipsen. I would also like to warmly thank François Garnier who had a long and distinguished career at Ipsen, making a big impact on the development of our company.' Mari Scheiffele said, 'I am honored to step into the role of Chief Product Officer at such an exciting time for our company. I am committed to driving innovation, fostering a culture of excellence, and continuing to work with our teams to deliver impact for our customers and patients.' Andreas Gerber said, 'I am thrilled to join Ipsen to lead the International Region and to work, together, with a world-class team to make a real impact on patients' everyday lives. I am looking forward to driving our innovative medicines across the portfolio to create access and adoption for patients and customers worldwide and to realize the full potential of our transformative therapies.' Caroline Sitbon added, 'It is an honor to take the General Counsel and General Secretary role and be part of this dynamic and fast-growing organization committed to advancing science for patients and consumers. I am very excited to have the opportunity to lead a highly qualified team that ensures our commitment to remain unwavering in compliance and integrity'. ABOUT IPSEN We are a global biopharmaceutical company with a focus on bringing transformative medicines to patients in three therapeutic areas: Oncology, Rare Disease and Neuroscience. Our pipeline is fueled by internal and external innovation and supported by nearly 100 years of development experience and global hubs in the U.S., France and the U.K. Our teams in more than 40 countries and our partnerships around the world enable us to bring medicines to patients in more than 80 countries. Ipsen is listed in Paris (Euronext: IPN) and in the U.S. through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information, visit IPSEN CONTACTS InvestorsKhalid Deojee +33 6 66 01 95 26 MediaSally Bain +1 857 32 00 517Anne Liontas +33 6 69 09 12 96 Disclaimers and/or Forward-Looking StatementsThe forward-looking statements, objectives and targets contained herein are based on Ipsen's management strategy, current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. All of the above risks could affect Ipsen's future ability to achieve its financial targets, which were set assuming reasonable macroeconomic conditions based on the information available today. Use of the words 'believes', 'anticipates' and 'expects' and similar expressions are intended to identify forward-looking statements, including Ipsen's expectations regarding future events, including regulatory filings and determinations. Moreover, the targets described in this document were prepared without taking into account external-growth assumptions and potential future acquisitions, which may alter these parameters. These objectives are based on data and assumptions regarded as reasonable by Ipsen. These targets depend on conditions or facts likely to happen in the future, and not exclusively on historical data. Actual results may depart significantly from these targets given the occurrence of certain risks and uncertainties, notably the fact that a promising medicine in early development phase or clinical trial may end up never being launched on the market or reaching its commercial targets, notably for regulatory or competition reasons. Ipsen must face or might face competition from generic medicine that might translate into a loss of market share. Furthermore, the research and development process involves several stages each of which involves the substantial risk that Ipsen may fail to achieve its objectives and be forced to abandon its efforts with regards to a medicine in which it has invested significant sums. Therefore, Ipsen cannot be certain that favorable results obtained during preclinical trials will be confirmed subsequently during clinical trials, or that the results of clinical trials will be sufficient to demonstrate the safe and effective nature of the medicine concerned. There can be no guarantees a medicine will receive the necessary regulatory approvals or that the medicine will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Other risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and healthcare legislation; global trends toward healthcare cost containment; technological advances, new medicine and patents attained by competitors; challenges inherent in new-medicine development, including obtaining regulatory approval; Ipsen's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Ipsen's patents and other protections for innovative medicines; and the exposure to litigation, including patent litigation, and/or regulatory actions. Ipsen also depends on third parties to develop and market some of its medicines which could potentially generate substantial royalties; these partners could behave in such ways which could cause damage to Ipsen's activities and financial results. Ipsen cannot be certain that its partners will fulfil their obligations. It might be unable to obtain any benefit from those agreements. A default by any of Ipsen's partners could generate lower revenues than expected. Such situations could have a negative impact on Ipsen's business, financial position or performance. Ipsen expressly disclaims any obligation or undertaking to update or revise any forward-looking statements, targets or estimates contained in this press release to reflect any change in events, conditions, assumptions or circumstances on which any such statements are based, unless so required by applicable law. Ipsen's business is subject to the risk factors outlined in its registration documents filed with the French Autorité des Marchés Financiers. The risks and uncertainties set out are not exhaustive and the reader is advised to refer to Ipsen's latest Universal Registration Document, available on Attachment Ipsen PR_ELT Changes_23072025Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
